Drug intelligence / Profile preview

AMG 581

Development stage: Phase 1
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

AMG 581 is a small molecule drug developed by Amgen for the treatment of schizophrenia and schizoaffective disorder. It was investigated as an oral antipsychotic agent, but its precise mechanism of action has not been publicly disclosed. Clinical development included phase 1 studies to assess safety, tolerability, and pharmacokinetics in both healthy subjects and patients with schizophrenia or schizoaffective disorder. No further development beyond phase 1 has been reported[1][2][7].

Beyond the preview

Go deeper on AMG 581.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 581.

Explore the full profile